Mostra i principali dati dell'item

dc.contributor.authorRíos-Luci, Carla
dc.contributor.authorDomínguez-Kelly, Raquel
dc.contributor.authorLeón, Leticia G
dc.contributor.authorDíaz Rodríguez, María Elena 
dc.contributor.authorFreire, Raimundo
dc.contributor.authorPandiella Alonso, Atanasio 
dc.contributor.authorCikotiene, Inga
dc.contributor.authorPadrón, José M
dc.date.accessioned2025-11-24T09:33:11Z
dc.date.available2025-11-24T09:33:11Z
dc.date.issued2011-11-15
dc.identifier.citationRíos-Luci, C., Domínguez-Kelly, R., León, L. G., Díaz-Rodríguez, E., Freire, R., Pandiella, A., ... & Padrón, J. M. (2011). A modular approach to trim cellular targets in anticancer drug discovery. Bioorganic & medicinal chemistry letters, 21(22), 6641-6645.es_ES
dc.identifier.issn0960-894X
dc.identifier.urihttp://hdl.handle.net/10366/167984
dc.description.abstract[EN]A Phenotypic Drug Discovery strategy was applied to study a set of pyrimidine analogs prepared by means of intramolecular oxidation-reduction reactions of N-substituted-N-(2,6-disubstituted-5-nitro-4-pyrimidinyl)aminoacetic acid methyl esters in basic media. The combined and rational use of specific assays allowed in short time reducing from all possible cellular targets to those involved in metaphase to anaphase transition.es_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPhenotypic Drug Discoveryes_ES
dc.subjectAntitumor agentses_ES
dc.subjectCell cyclees_ES
dc.subjectMitotic arrestes_ES
dc.subjectStructure–activity relationshipses_ES
dc.subject.meshDrug Discovery *
dc.subject.meshPyrimidines *
dc.subject.meshStructure-Activity Relationship *
dc.subject.meshCell Cycle *
dc.subject.meshOxidation-Reduction *
dc.subject.meshHumans *
dc.subject.meshAnaphase *
dc.subject.meshCell Line *
dc.subject.meshAntineoplastic Agents *
dc.subject.meshMetaphase *
dc.subject.meshNeoplasms *
dc.titleA modular approach to trim cellular targets in anticancer drug discoveryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1016/j.bmcl.2011.09.069es_ES
dc.subject.unesco2302 Bioquímicaes_ES
dc.subject.unesco2302.06 Quimioterapiaes_ES
dc.subject.unesco2407 Biología Celulares_ES
dc.identifier.doi10.1016/j.bmcl.2011.09.069
dc.relation.projectIDRTICC RD06/0020/1046es_ES
dc.relation.projectIDD06/0020/0041es_ES
dc.relation.projectIDCTQ2008-06806-C02-01/BQUes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid21986585
dc.identifier.essn1464-3405
dc.journal.titleBioorganic & medicinal chemistry letterses_ES
dc.volume.number21es_ES
dc.issue.number22es_ES
dc.page.initial6641es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsrelación estructura-actividad *
dc.subject.decspirimidinas *
dc.subject.decsdescubrimiento de fármacos *
dc.subject.decsneoplasias *
dc.subject.decsmetafase *
dc.subject.decsciclo celular *
dc.subject.decshumanos *
dc.subject.decsantineoplásicos *
dc.subject.decsoxidación-reducción *
dc.subject.decslínea celular *
dc.subject.decsanafase *


Files in questo item

Thumbnail

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional